Intellectual Product – Page 16

Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing

6 months ago talkbio0Tagged AXS-12, Axsome, Encore, File (record), Narcolepsy, NDA, Phase 3 Clinical Trials, United States Food and Drug Administration

Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA

Biden Administration Proposes Expanded Coverage of Anti-Obesity Medications for Medicare and Medicaid Enrollees

6 months ago talkbio0Tagged Biden administration, Drug Prescriptions, Health Care Reform, Medicaid, Medicare, Obesity

Biden Administration, Obesity Drug Coverage, Medicare, Medicaid, Prescription Drug Costs, Healthcare Reform

Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?

6 months ago talkbio0Tagged Bhattacharya, Biomedical Research, Jay, Leadership, NIH Mouse, Speed, Transplant Registry Unified Management Program, VWA1 gene

Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research

Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment

6 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Practice Guideline, gene therapy, Hematological Disease, Hematology (discipline), Improvement, Quality

Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

6 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

6 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Clinical Development, lexicon, LX9211, LX9851, R&D pipeline, restructuring, United States Food and Drug Administration, Zynquista

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

6 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Chronic Kidney Diseases, Clinical Development, commercial, lexicon, restructuring, setbacks, Surgical aspects, United States Food and Drug Administration

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring

Trump Nominates Surgeon Martin Makary for FDA Commissioner Amid Criticism of COVID Mandates

6 months ago talkbio0Tagged COVID, Makary, mandates, Martin, nomination, Surgeon, Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Martin Makary, COVID mandates, surgeon, nomination

Dr. Mehmet Oz Nominated to Lead Centers for Medicare and Medicaid Services

6 months ago talkbio0Tagged Dr., healthcare leadership, Medicaid, Medicaid Services, Medicare, nomination, ounce, Transplant Registry Unified Management Program

Dr. Mehmet Oz, Medicare, Medicaid, Centers for Medicare and Medicaid Services, Trump nomination, healthcare leadership

FDA Issues Complete Response Letter to Astellas for IZERVAY Supplemental New Drug Application

6 months ago talkbio0Tagged Age related macular degeneration, Astellas, Complete, Geographic Atrophy, IZERVAY, New Drug Application, Response process, United States Food and Drug Administration

FDA, Astellas, IZERVAY, geographic atrophy, age-related macular degeneration, Complete Response Letter, supplemental New Drug Application